Peer-reviewed veterinary case report
Oxyclozanide drug tested against common small animal bacteria
By Levinson, Matthew R et al.·Published in Veterinary dermatology·2019·Animal Dermatology Clinic, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The in vitro antibacterial activity of the anthelmintic drug oxyclozanide against common small animal bacterial pathogens.
Plain-English summary
A study found that oxyclozanide, a drug typically used to treat parasites in livestock, showed antibacterial activity against a common skin infection in dogs caused by Staphylococcus pseudintermedius. This is important because some strains of this bacteria are resistant to standard antibiotics. The drug was effective in laboratory tests against both sensitive and resistant strains of the bacteria, suggesting it could be a potential treatment option. However, more research is needed to see if oxyclozanide can be used safely and effectively on pets.
People also search for: dog skin infection treatment · antibiotic resistance in dogs · oxyclozanide for dog infections
Abstract
BACKGROUND: Repurposing existing drugs is one approach to address the growing concerns of multi-drug resistant bacterial pathogens in veterinary medicine. Oxyclozanide is in the anthelmintic drug class salicylanilide, which has been used primarily as a treatment and preventative for Fasciola hepatica in ruminants. The antimicrobial activity of oxyclozanide has been studied in human medicine; its activity against common small animal bacterial pathogens such as Staphylococcus pseudintermedius has yet to be determined. OBJECTIVE: The aim of this study was to measure and establish the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of oxyclozanide against S. pseudintermedius and other common small animal bacterial pathogens. METHODS AND MATERIALS: The MIC and MPC of oxyclozanide were determined from eighteen meticillin sensitive S. pseudintermedius (MSSP) isolates and eleven meticillin-resistant S. pseudintermedius (MRSP), as well as single isolates of Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and Enterococcus faecalis. RESULTS: The MIC of the eighteen meticillin-sensitive S. pseudintermedius isolates was 0.5-1 μg/mL and the MPC ranged between 16 and 32 μg/mL. The MIC of the eleven meticillin-resistant strains of S. pseudintermedius ranged from 0.5 to 2 μg/mL with a MPC ranging between 16 and 32 μg/mL. A single isolate of meticillin-resistant S. aureus (MRSA) had an MIC of 1 μg/mL and MPC 16 μg/mL. No inhibition of growth was seen at the concentrations tested for bacterial isolate strains E. coli, P. aeruginosa and E. faecalis. CONCLUSION AND CLINICAL IMPORTANCE: Oxyclozanide demonstrated in-vitro antibacterial activity against meticillin-resistant S. pseudintermedius. Further studies are needed to evaluate the potential use of oxyclozanide as a topical bactericidal agent.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31062461/